Header Logo

Connection

ERIC ROHREN to Female

Back to Details
This is a "connection" page, showing publications ERIC ROHREN has written about Female.
ERIC ROHREN
Connection Strength
0.205
Female
  1. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
    View in: PubMed
    Score: 0.025
  2. Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. AJR Am J Roentgenol. 2016 Mar; 206(3):623-31.
    View in: PubMed
    Score: 0.021
  3. Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study. AJR Am J Roentgenol. 2015 Nov; 205(5):1094-101.
    View in: PubMed
    Score: 0.020
  4. Qualitative FDG PET Image Assessment Using Automated Three-Segment MR Attenuation Correction Versus CT Attenuation Correction in a Tertiary Pediatric Hospital: A Prospective Study. AJR Am J Roentgenol. 2015 Sep; 205(3):652-8.
    View in: PubMed
    Score: 0.020
  5. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12.
    View in: PubMed
    Score: 0.020
  6. PET/Computed Tomography and Patient Outcomes in Melanoma. PET Clin. 2015 Apr; 10(2):243-54.
    View in: PubMed
    Score: 0.019
  7. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med. 2011 Feb; 36(2):96-100.
    View in: PubMed
    Score: 0.014
  8. Individualized functional magnetic resonance imaging neuromodulation enhances visuospatial perception: a proof-of-concept study. Philos Trans R Soc Lond B Biol Sci. 2024 Dec 02; 379(1915):20230083.
    View in: PubMed
    Score: 0.009
  9. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978.
    View in: PubMed
    Score: 0.005
  10. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14.
    View in: PubMed
    Score: 0.004
  11. (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Dec; 40(12):1809-16.
    View in: PubMed
    Score: 0.004
  12. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8.
    View in: PubMed
    Score: 0.004
  13. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol. 2012 Mar; 198(3):W304-14.
    View in: PubMed
    Score: 0.004
  14. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant? Acad Radiol. 2012 May; 19(5):535-41.
    View in: PubMed
    Score: 0.004
  15. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
    View in: PubMed
    Score: 0.004
  16. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
    View in: PubMed
    Score: 0.004
  17. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94.
    View in: PubMed
    Score: 0.004
  18. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
    View in: PubMed
    Score: 0.003
  19. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
    View in: PubMed
    Score: 0.003
  20. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8.
    View in: PubMed
    Score: 0.003
  21. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009 Jun; 10(6):606-14.
    View in: PubMed
    Score: 0.003
  22. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11.
    View in: PubMed
    Score: 0.003
  23. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.